Industry & Policy News

[Aegle Therapeutics Corp. (PR Newswire)] Aegle Therapeutics Corp. announced the first patient has been dosed in the Phase I/IIa clinical trial of AGLE-102™ for the treatment of severe second-degree burns.

[Tonix Pharmaceuticals Holding Corp.] Tonix Pharmaceuticals Holding Corp. announced that it received the official written response from a Type B pre-Investigational New Drug Application meeting with the US FDA to develop TNX-8011 as a potential vaccine to protect against mpox disease and smallpox.

[Fierce Pharma (Regeneron)] Regeneron has scored an FDA nod for Veopoz as the first treatment for the ultra-rare inherited immune condition Chaple disease. The disease, which is also known as CD55-deficient protein-losing enteropathy, has a global patient population of fewer than 100 people.

[OncLive] The FDA granted an orphan drug designation to the IgG1k type murine monoclonal antibody MAb-AR20.5 for the treatment of patients with pancreatic cancer, according to an announcement from CanariaBio.

[Sylvester Comprehensive Cancer Center (News Medical Life Sciences)] Researchers with Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine have been awarded a grant from the U.S. Department of Defense (DoD)'s Congressionally Directed Medical Research Program to target chemotherapy resistance in pancreatic cancer.

[Memorial Sloan Kettering Cancer Center] Chi Nguyen, a PhD student attending the Gerstner Sloan Kettering Graduate School of Biomedical Sciences (GSK), has been awarded the 2023 Chairman’s Prize.